The U.K. government aims to spur the development of rockets that gobble themselves up on the way to orbit.
The Ministry of Defence’s Defence & Security Accelerator (DASA) has pledged £90,000 — about $117,000 USD at current exchange rates — for the continued development of the “autophage” rocket engine, which is being built by researchers at the University of Glasgow in Scotland.
The tech is a great fit for small rockets “because scaling down a rocket reduces the mass of the propellant more than it reduces the mass of all the other components, including the tanks that hold the propellant itself,” Patrick Harkness, of the University of Glasgow’s James Watt
Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 Meeting
–Oral Presentation to Provide Update on Phase 1/2 Clinical Trial Data of RP-L201 for Leukocyte Adhesion Deficiency-I–
–Poster Presentation to Highlight Preclinical Data on RP-L401 for Infantile Malignant Osteopetrosis–
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces two presentations at the European Society for Immunodeficiencies (ESID) 2020 Meeting to be held virtually October 14-17, 2020. An oral presentation will provide an update on data from the Phase 1/2 clinical trial of RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I). An e-poster will highlight preclinical study data on RP-L401 for Infantile Malignant Osteopetrosis (IMO).
Additional presentation details can be found below:
Title: A Phase 1/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Results from